Insider Selling: Arvinas, Inc. (NASDAQ:ARVN) Insider Sells 9,020 Shares of Stock

Arvinas, Inc. (NASDAQ:ARVN) insider Ian Taylor sold 9,020 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.71, for a total value of $150,724.20. Following the transaction, the insider now owns 159,121 shares in the company, valued at approximately $2,658,911.91. This trade represents a 5.36 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Arvinas Stock Performance

NASDAQ ARVN opened at $17.08 on Thursday. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -6.16 and a beta of 1.88. The stock’s 50 day moving average price is $18.38 and its two-hundred day moving average price is $22.76. Arvinas, Inc. has a 52 week low of $16.07 and a 52 week high of $51.51.

Arvinas (NASDAQ:ARVN) last released its earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the previous year, the business posted ($2.53) EPS. On average, equities research analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ARVN shares. HC Wainwright restated a “buy” rating and set a $87.00 target price on shares of Arvinas in a report on Wednesday, December 11th. Oppenheimer raised their target price on Arvinas from $40.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Arvinas in a report on Friday, February 7th. Stephens assumed coverage on Arvinas in a report on Monday, November 18th. They set an “overweight” rating and a $55.00 target price on the stock. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $82.00 price objective (down previously from $88.00) on shares of Arvinas in a report on Wednesday, February 12th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $60.00.

Institutional Investors Weigh In On Arvinas

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Arvinas by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 7,062,561 shares of the company’s stock valued at $135,389,000 after acquiring an additional 56,561 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Arvinas by 6.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company’s stock worth $78,656,000 after purchasing an additional 249,295 shares during the last quarter. RTW Investments LP increased its position in shares of Arvinas by 19.8% during the 4th quarter. RTW Investments LP now owns 3,334,308 shares of the company’s stock worth $63,919,000 after purchasing an additional 551,979 shares during the last quarter. FMR LLC increased its position in shares of Arvinas by 7.6% during the 3rd quarter. FMR LLC now owns 2,883,604 shares of the company’s stock worth $71,023,000 after purchasing an additional 204,317 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Arvinas by 18.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock worth $57,371,000 after purchasing an additional 367,343 shares during the last quarter. Institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.